Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.
You may also be interested in...
BMS Jumps Ahead With LAG-3 Melanoma Data
LAG-3 antibody shows improved PFS when combined with Opdivo in metastatic or inoperable melanoma. Bristol Myers Squibb still awaits overall survival data but could have its second dual checkpoint inhibitor pairing.
Keytruda's Broad Confirmatory Trials Suggest Evolution Of US FDA’s Accelerated Approval Model
FDA’s most recent accelerated approvals for Merck’s Keytruda call for confirmatory trials in a broader patient population than the approved indications, in the latest example of FDA’s growing comfort with multi-purpose confirmatory trials in the PD-1/PD-L1 inhibitor space.
Bristol Taking A Cautious Approach To Triple Immuno-Oncology Combos
The company is starting to explore triple immuno-oncology combinations, Head of Oncology-Global Clinical Research Jean Viallet said, but IO development is mainly focused on expanding the firm's existing double combination, Opdivo and Yervoy, to earlier treatment and new tumors.